5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
1
NCNA Quote, Financials, Valuation and Earnings
Last price:
$0.11
Seasonality move
:
3.2%
Day range:
$0.25 - $0.42
52-week range:
$0.25 - $10.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.24x
Volume:
39.4M
Avg. volume:
7.4M
1-year change:
-92.3%
Market cap:
$1.8M
Revenue:
--
EPS (TTM):
-$10.50
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -84.24% | -7.08% | $10.01 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
$15.3M | -$0.01 | -100% | -71.23% | $7.44 |
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
$0.30 | $104.00 | $1.8M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.30 | $1.71 | $77.2M | -- | $0.00 | 0% | 0.43x |
|
AUTL
Autolus Therapeutics PLC
|
$1.23 | $10.01 | $327.3M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.38 | $17.94 | $3.5M | -- | $0.00 | 0% | 1.44x |
|
MREO
Mereo BioPharma Group PLC
|
$2.39 | $7.44 | $380M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$69.14 | $94.10 | $5.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 3.631 | 36.44% | 2.60x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 1.803 | -- | 10.47x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.393 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$75.9M | -51.91% | -51.91% | -196479.31% | -$61.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$14.7M | -- | -- | -- | -$9.4M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
NuCana PLC vs. Competitors
-
Which has Higher Returns NCNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -2303.38%. NuCana PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$0.32 -- ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About NCNA or ADAP?
NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 34440.02%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 468.75%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC0 1 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is NCNA or ADAP More Risky?
NuCana PLC has a beta of 1.639, which suggesting that the stock is 63.921% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock NCNA or ADAP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or ADAP?
NuCana PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. NuCana PLC's net income of -$836.1K is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, NuCana PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 0.43x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$836.1K ADAPAdaptimmune Therapeutics PLC0.43x -- $3.2M -$74.2M
-
Which has Higher Returns NCNA or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -95193.1%. NuCana PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -51.91%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$0.32 -- AUTLAutolus Therapeutics PLC-- -$0.09 $427.3M -
What do Analysts Say About NCNA or AUTL?
NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 34440.02%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.01 which suggests that it could grow by 713.91%. Given that NuCana PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe NuCana PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC0 1 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is NCNA or AUTL More Risky?
NuCana PLC has a beta of 1.639, which suggesting that the stock is 63.921% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.
-
Which is a Better Dividend Stock NCNA or AUTL?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or AUTL?
NuCana PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $29K. NuCana PLC's net income of -$836.1K is higher than Autolus Therapeutics PLC's net income of -$27.6M. Notably, NuCana PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$836.1K AUTLAutolus Therapeutics PLC-- -- $29K -$27.6M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$0.32 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About NCNA or BDRX?
NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 34440.02%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1200.28%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC0 1 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is NCNA or BDRX More Risky?
NuCana PLC has a beta of 1.639, which suggesting that the stock is 63.921% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$836.1K is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 1.44x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$836.1K BDRXBiodexa Pharmaceuticals PLC1.44x -- -- --
-
Which has Higher Returns NCNA or MREO?
Mereo BioPharma Group PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$0.32 -- MREOMereo BioPharma Group PLC-- -$0.05 -- -
What do Analysts Say About NCNA or MREO?
NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 34440.02%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.44 which suggests that it could grow by 211.17%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC0 1 0 MREOMereo BioPharma Group PLC6 0 0 -
Is NCNA or MREO More Risky?
NuCana PLC has a beta of 1.639, which suggesting that the stock is 63.921% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.542%.
-
Which is a Better Dividend Stock NCNA or MREO?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or MREO?
NuCana PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. NuCana PLC's net income of -$836.1K is higher than Mereo BioPharma Group PLC's net income of -$7M. Notably, NuCana PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$836.1K MREOMereo BioPharma Group PLC-- -- -- -$7M
-
Which has Higher Returns NCNA or VRNA?
Verona Pharma PLC has a net margin of -- compared to NuCana PLC's net margin of -21.4%. NuCana PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$0.32 -- VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About NCNA or VRNA?
NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 34440.02%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 36.1%. Given that NuCana PLC has higher upside potential than Verona Pharma PLC, analysts believe NuCana PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC0 1 0 VRNAVerona Pharma PLC7 0 0 -
Is NCNA or VRNA More Risky?
NuCana PLC has a beta of 1.639, which suggesting that the stock is 63.921% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.
-
Which is a Better Dividend Stock NCNA or VRNA?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or VRNA?
NuCana PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. NuCana PLC's net income of -$836.1K is higher than Verona Pharma PLC's net income of -$16.3M. Notably, NuCana PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$836.1K VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
